Disc Medicine, Inc. (IRON)
NASDAQ: IRON · Real-Time Price · USD
59.00
-0.76 (-1.27%)
At close: Aug 1, 2025, 4:00 PM
58.97
-0.03 (-0.05%)
After-hours: Aug 1, 2025, 4:26 PM EDT
CTI BioPharma Stock Forecast
Stock Price Forecast
The 12 analysts that cover CTI BioPharma stock have a consensus rating of "Strong Buy" and an average price target of $92.08, which forecasts a 56.07% increase in the stock price over the next year. The lowest target is $57 and the highest is $132.
Price Target: $92.08 (+56.07%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CTI BioPharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 4 | 5 |
| Buy | 6 | 7 | 7 | 6 | 6 | 7 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 9 | 10 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Strong Buy Initiates $86 | Strong Buy | Initiates | $86 | +45.76% | Jul 21, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Initiates $85 | Buy | Initiates | $85 | +44.07% | Jul 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $118 | Strong Buy | Reiterates | $118 | +100.00% | Jul 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $118 | Strong Buy | Reiterates | $118 | +100.00% | Jun 17, 2025 |
| Raymond James | Raymond James | Strong Buy Initiates $89 | Strong Buy | Initiates | $89 | +50.85% | Jun 11, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
26.29M
EPS This Year
-4.79
from -3.96
EPS Next Year
-5.18
from -4.79
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 57.8M | 255.2M | ||
| Avg | n/a | 26.3M | 122.3M | ||
| Low | n/a | n/a | 9.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 870.6% | ||
| Avg | - | - | 365.0% | ||
| Low | - | - | -63.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -4.35 | -4.22 | -1.05 | ||
| Avg | -4.79 | -5.18 | -4.18 | ||
| Low | -5.26 | -7.72 | -8.94 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.